Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
197 Results for "
elastase
" in MedChemExpress (MCE) Product Catalog:
Products (197)
197 Results for "elastase" in MCE Product Catalog:
Cat. No.: HY-N17881
CAS No.: 1070883-79-2
Target:
Cat. No.: HY-120039
CAS No.: 163660-53-5
Target:
Research Areas:
(R)-MDL-101146 is the R-isomer of MDL-101146. MDL-101146 is an orally active, competitive and reversible inhibitor against human neutrophil elastase (HNE) with a Ki value of 25 nM. MDL-101146 inhibits HNE-induced hemorrhage in hamsters. MDL-101146 is promising for research of emphysema, rheumatoid arthritis, chronic bronchitis, cystic fibrosis, adult respiratory distress syndrome and glomerulonephritis .
Cat. No.: HY-120039A
CAS No.: 163660-59-1
Target:
Research Areas:
(S)-MDL-101146 is the S-isomer of MDL-101146. MDL-101146 is an orally active, competitive and reversible inhibitor against human neutrophil elastase (HNE) with a Ki value of 25 nM. MDL-101146 inhibits HNE-induced hemorrhage in hamsters. MDL-101146 is promising for research of emphysema, rheumatoid arthritis, chronic bronchitis, cystic fibrosis, adult respiratory distress syndrome and glomerulonephritis .
Cat. No.: HY-136705
CAS No.: 111682-13-4
Synonyms: MSACK
Target:
Research Areas:
MeO-Suc-Ala-Ala-Pro-Ala-CMK (MSACK) is an inhibitor of human neutrophil elastase (HNE), with an IC50 of 20.3 μM. MeO-Suc-Ala-Ala-Pro-Ala-CMK can inhibit the hydrolysis of substrates such as elastin in lung tissue by HNE. MeO-Suc-Ala-Ala-Pro-Ala-CMK can be used in the research of related diseases such as chronic obstructive pulmonary disease (COPD) .
Cat. No.: HY-P85080
Synonyms: MME; EPN; Neprilysin; Atriopeptidase; Common acute lymphocytic leukemia antigen; CALLA; Enkephalinase; Neutral endopeptidase 24.11; NEP; Neutral endopeptidase; Skin fibroblast elastase; SFE; CD antigen CD10
Cat. No.: HY-11046
CAS No.: 1015439-77-6
Target:
Research Areas:
KRP-109 is a neutrophil elastase (NE) inhibitor with activity in reducing lung inflammation. KRP-109 improves survival in mouse models and reduces the number of neutrophils and inflammation in the alveolar walls. KRP-109 significantly reduced cell and neutrophil counts in bronchoalveolar lavage fluid, as well as cytokine levels such as interleukin 1β and macrophage inflammatory protein 2. KRP-109 can be used in the research of severe pneumonia .
Cat. No.: HY-11046A
CAS No.: 1275996-50-3
Target:
Research Areas:
KRP-109 is a neutrophil elastase (NE) inhibitor with activity in reducing lung inflammation. KRP-109 improves survival in mouse models and reduces the number of neutrophils and inflammation in the alveolar walls. KRP-109 significantly reduced cell and neutrophil counts in bronchoalveolar lavage fluid, as well as cytokine levels such as interleukin 1β and macrophage inflammatory protein 2. KRP-109 can be used in the research of severe pneumonia .
Cat. No.: HY-111457R
CAS No.: 2117404-84-7
Target:
Research Areas:
BAY-677 (Standard) is the analytical standard of BAY-677 (HY-111457). This product is intended for research and analytical applications. BAY-677 is an inactive control for BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM . BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC) .
Cat. No.: HY-168948
CAS No.: 3063543-24-5
Quorum sensing-IN-9 (Compound 7d) inhibits quorum sensing in Pseudomonas aeruginosa by binding PqsR proteins. Quorum sensing-IN-9 inhibits the expression of quorum sensing systems related genes lasB, rhlA and pqsA, blocks the generation of virulence factors elastase, pyocyanin and rhamnolipid. Quorum sensing-IN-9 destorys the motility of P. aeruginosa, inhibits the biofilm formation, decreasing the virulence and pathogenicity of P. aeruginosa. Quorum sensing-IN-9 exhibits anti-infectious activity in Galleria mellonella larval model .
Cat. No.: HY-10242
CAS No.: 300832-84-2
Synonyms: BILN 2061; BILN 2061ZW
Target:
Research Areas:
Ciluprevir (BILN 2061; BILN 2061ZW) is an orally active macrocyclic peptide inhibitor of hepatitis C virus (HCV)NS3 protease, with an IC50 of 3 nM. Ciluprevir has Kᵢ values of 0.66 nM and 0.30 nM against genotypes 1b and 1a, respectively. Ciluprevir inhibits HCV RNA replication with an EC50 of 1.2 nM, and its EC50 values against genotypes 1b and 1a are 3 nM and 4 nM, respectively. Ciluprevir shows no significant inhibition against human leukocyte elastase and hepatic cathepsin B. Ciluprevir can be used for genotype 1 HCV infection .
Cat. No.: HY-181647
CAS No.: 2762675-42-1
LasB-IN-3 is a protease elastase (LasB) inhibitor of Pseudomonas aeruginosa with an IC50 value of 8.5 nM. LasB-IN-3 shows an IC50 of 58.9 nM for the Met128Val mutant. LasB-IN-3 binds to active sites of wild-type and Met128Val mutant LasB, coordinates zinc ions, forms hydrogen bonds and CH-π interactions, and inhibits LasB proteolytic activity. LasB-IN-3 increases survival rate in LasB-induced acute lung injury mice models. LasB-IN-3 can be used for the research of Pseudomonas aeruginosa infection .
Cat. No.: HY-N17365
CAS No.: 1275622-20-2
Target:
Cat. No.: HY-101283R
CAS No.: 1435265-06-7
Research Areas:
HCH6-1 (Standard) is the analytical standard of HCH6-1 (HY-101283). This product is intended for research and analytical applications. HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .
Category:
Cat. No.: HY-150085
CAS No.: 2393881-77-9
Target:
Research Areas:
GSK951 is a highly potent, selective, and reversibly covalent KLK5 inhibitor, with an IC50 of approximately 250 pM and a pIC50 of 9.6 against hKLK5. It exhibits over 100-fold selectivity over KLK7, KLK14, matriptase, and elastase. GSK951 binds to the catalytic site of KLK5 via covalent interaction with the catalytic serine, with a slow dissociation rate. GSK951 improves skin barrier function, reduces transepidermal water loss, decreases the expression of proinflammatory cytokines, and inhibits the elevated KLK5 protease activity in the stratum corneum. GSK951 can be used in studies related to skin barrier dysfunction.
Cat. No.: HY-163982
Research Areas:
FOXJ1 agonist 1 (compound 16c) is an orally effective small molecule that can effectively enhance the expression of FOXJ1. Foxj1-IN-1 acts on the mammalian airway system composed of multiciliated cells (MCC) to prevent the development and onset of chronic obstructive pulmonary disease (COPD). Foxj1-IN-1 can induce the production of motile cilia in the respiratory system of zebrafish and mammals, and inhibit elastase-induced COPD mouse models. Foxj1-IN-1 has good liver microsomal stability, in vivo PK curve and AUC; it has no significant inhibition of CYP and hERG, and does not have significant cytotoxicity .
Cat. No.: HY-173270
Antibacterial synergist 3 is a dual-acting inhibitor of biofilm (IC50 of PAO1: 0.40 μM and IC50 of PA14: 1.45 μM). Antibacterial synergist 3 reduces virulence production by inhibiting the quorum sensing (QS) system and induces iron deficiency in P. aeruginosa PAO1. Antibacterial synergist 3 enhances the efficacy of Tobramycin (HY-B0441) and Ciprofloxacin (HY-B0356) in a mouse wound infection model. Antibacterial synergist 3 can be used for the research of P. aeruginosa infections .
Cat. No.: HY-106899A
CAS No.: 143445-03-8
Synonyms: (rel)-L-680573
Research Areas:
(rel)-MK 287 ((rel)-L-680573) is a relative configuration of MK 287. MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
Cat. No.: HY-117811
CAS No.: 143490-81-7
Synonyms: L-680574
Research Areas:
(R,R)-MK 287 (L-680574) is a tetrahydrofuran derivative that potently inhibits the binding of [3H]C18-PAF to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes with Ki values of 6.1, 3.2, and 5.49 nM, respectively. (R,R)-MK 287 potently and selectively inhibits PAF-induced platelet aggregation (ED50=56 nM) and elastase release from PMNs (ED50=4.4 nM). (R,R)-MK 287 inhibits PAF-induced lethality in mice (ED50=0.8 mg/kg, po) and PAF-induced bronchospasm in guinea pigs (ED50=0.18 mg/kg) .
Cat. No.: HY-181762
Research Areas:
Multitarget AD-IN-6 (Compound 39) is a multi-target inhibitor, with an IC50 of 15.54 μM against PDE4B, 15.15 μM against PDE7A, 8.39 μM against PDE3A, and a Kd of 37.7 μM against CHIT1. Multitarget AD-IN-6 acts as a TRPA1 antagonist, reduces the level of the NLRP3 inflammasome multiprotein complex to inhibit its activation, while inhibiting PDE4B, PDE7A and CHIT1, and decreasing the phosphorylation of NF-κB. Multitarget AD-IN-6 improves the pathology of elastase-induced emphysema in mice. Multitarget AD-IN-6 is applicable for the research of chronic obstructive pulmonary disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
